Adelle Diagnostics
Adelle Diagnostics is a women-owned MedTech startup specializing in AI-based biomarker discovery and development of minimally invasive blood-based diagnostic tests for neurodegenerative diseases, particularly Normal Pressure Hydrocephalus (NPH). The company integrates multi-omics technologies, including RNA sequencing and mass spectrometry, with machine learning to generate molecular signatures from patient cerebrospinal fluid, enabling precise diagnosis and prediction of shunt surgery benefits. Adelle Diagnostics aims to improve patient outcomes by providing rapid, cost-effective diagnostic tools that support personalized treatment decisions and accelerate drug development. The company is positioned as a pioneer in biomarker discovery for neurodegenerative diseases, addressing a critical unmet need in a growing market driven by aging populations and increasing disease incidence.
Adelle Diagnostics
Adelle Diagnostics is a women-owned MedTech startup specializing in AI-based biomarker discovery and development of minimally invasive blood-based diagnostic tests for neurodegenerative diseases, particularly Normal Pressure Hydrocephalus (NPH). The company integrates multi-omics technologies, including RNA sequencing and mass spectrometry, with machine learning to generate molecular signatures from patient cerebrospinal fluid, enabling precise diagnosis and prediction of shunt surgery benefits. Adelle Diagnostics aims to improve patient outcomes by providing rapid, cost-effective diagnostic tools that support personalized treatment decisions and accelerate drug development. The company is positioned as a pioneer in biomarker discovery for neurodegenerative diseases, addressing a critical unmet need in a growing market driven by aging populations and increasing disease incidence.